Keenova Therapeutics plc reports company news around its branded therapeutics portfolio for rare and unaddressed conditions. Recurring updates cover financial results, clinical publications, disease-awareness campaigns, and presentations involving products and programs such as Acthar Gel, XIAFLEX, TERLIVAZ, and collagenase clostridium histolyticum research.
The company's communications emphasize specialty therapeutic areas that include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. News also covers integration activity following its business combination, U.S. manufacturing operations, and portfolio performance drivers across established branded medicines.
Mallinckrodt (MNK) reported Q2 2025 financial results and provided guidance following its merger with Endo. Legacy Mallinckrodt achieved net sales of $485.1M (down 5.7% YoY, but up 8.5% excluding Therakos divestiture) and net income of $2.4M. Legacy Endo reported flat revenues of $447.8M with a net loss of $59.6M.
Key highlights include Acthar Gel's highest growth in over a decade (up 48.8% to $175.1M) and XIAFLEX's 9.4% growth to $138.6M. The combined company projects 2025 net sales of $3.57B-$3.62B and adjusted EBITDA of $1.10B-$1.13B. The planned spin-off of Par Health remains on track for Q4 2025, with expected net sales of $1.72B-$1.75B.
The company raised Acthar Gel's 2025 growth guidance to 20-30% from high-single digits and reaffirmed XIAFLEX's high-single digit growth outlook.Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.
The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.
Mallinckrodt (NYSE:MNK) and Endo have completed their merger to create a global therapeutics leader. Under the deal terms, Endo shareholders received $100 million in cash and will own 49.9% of Mallinckrodt, while pre-transaction Mallinckrodt shareholders retain 50.1% ownership.
The merger includes plans to spin off their combined generics and sterile injectables business (Par Health) as an independent company by Q4 2025. The company expects to achieve $150 million in annual pre-tax synergies by Year 3, with $75 million in the first year. A $1.35 billion secured credit facility was established to refinance debt and fund the transaction.
Post spin-off, the branded therapeutics company will seek NYSE listing. Siggi Olafsson continues as CEO, with Paul Efron serving as Board Chair of the combined entity.
Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025. The company will host an investor conference call at 8:30 a.m. ET.
Investors can participate through multiple channels, including a live dial-in registration system and an audio-only webcast. The presentation will also be accessible through Mallinckrodt's Investor Relations website.
Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.
The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.
Acthar Gel sales increased 12.3% to $115.4 million, marking its fifth consecutive quarter of growth. The SelfJect device now accounts for >70% of new prescriptions. INOmax EVOLVE DS delivery system is now in over 50 hospitals with 400+ systems placed.
The company's cash balance stood at $422.2 million, with total debt reduced by 47.5% YoY to $864.6 million. Mallinckrodt reaffirmed its 2025 guidance with expected net sales of $1.7-1.8 billion and Adjusted EBITDA of $480-520 million. The company is progressing toward completing its merger with Endo in H2 2025.
Mallinckrodt has announced the presentation of five clinical studies on TERLIVAZ® (terlipressin) at the 2025 Digestive Disease Week (DDW) in San Diego. The research focuses on treating hepatorenal syndrome (HRS) with rapid reduction in kidney function, also known as HRS-AKI.
TERLIVAZ is the first FDA-approved treatment for this rare condition, which affects over 42,000 Americans annually (0.01% of U.S. population). The presentations include one oral presentation and four posters, covering topics such as real-world treatment outcomes, comparative analysis between UK and US patients, and efficacy in patients with alcohol-associated liver disease.
The presentations will take place from May 3-6, 2025, featuring research on transplant waitlist status, treatment comparisons, and benefit-to-risk profiles. Important safety information indicates that TERLIVAZ may cause serious respiratory failure, particularly in patients with volume overload or acute-on-chronic liver failure Grade 3.